NeurotechMagProGet access
News & Press

ONWARD Medical Reports EUR 2.5M Q3 Revenue as ARC-EX Placements Grow 120%

ONWARD Medical11/3/2026ยท17d ago๐Ÿ‡ช๐Ÿ‡บ Europe

Summary

ONWARD Medical reported third-quarter 2026 revenue of EUR 2.5 million, of which EUR 2.0 million came from ARC-EX systems, and a cash balance of EUR 73.4 million at September 30. It said 88 ARC-EX systems were sold or supplied for paid evaluation, 120% more units than a year earlier, with most intended for home use, and that the device is now available at more than 170 clinics worldwide. In Q3 the company also secured a financing agreement of up to EUR 50 million with funds managed by BlackRock, drawing EUR 20 million to repay its previous lender. Its Empower BP pivotal study of ARC-IM for blood pressure instability after spinal cord injury has enrolled 31 participants at 16 sites, and feasibility studies reported first implants for mobility and bladder control.

Why it matters

Quarterly unit and revenue figures show how fast a spinal cord stimulation therapy is being adopted outside the clinic, with home use now the majority of placements. The numbers are company-reported, and the implantable ARC-IM therapy remains investigational.

#Neurostimulation

Want the full NeurotechMag Pro intelligence database?

Access 800+ papers, trials, patents, funding rounds and news items โ€” updated daily.

Start free trial
Already a member? Sign in